Skip header and navigation

26 records – page 1 of 3.

Adverse reactions between alcohol and drug products

https://policybase.cma.ca/en/permalink/policy805
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Policy Type
Policy resolution
Last Reviewed
2017-Mar-04
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.
Less detail

Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/en/permalink/policy11519
Date
2015-May-14
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Catastrophic prescription drug program

https://policybase.cma.ca/en/permalink/policy8841
Date
2007-Aug-22
Topics
Health systems, system funding and performance
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the Canadian Institute for Health Information and Statistics Canada to conduct a detailed study of the socio-economic profile of Canadians who have out-of-pocket prescription drug expenses to assess barriers to access and to design strategies that could be built into a catastrophic prescription drug program.
Policy Type
Policy resolution
Last Reviewed
2014-Mar-01
Date
2007-Aug-22
Topics
Health systems, system funding and performance
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the Canadian Institute for Health Information and Statistics Canada to conduct a detailed study of the socio-economic profile of Canadians who have out-of-pocket prescription drug expenses to assess barriers to access and to design strategies that could be built into a catastrophic prescription drug program.
Less detail

CMA's Response to Health Canada's Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa's Law)

https://policybase.cma.ca/en/permalink/policy11599
Date
2015-Jun-08
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

CMA statement authorizing marijuana for medical purposes (update 2015)

https://policybase.cma.ca/en/permalink/policy11514
Date
2015-Feb-28
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Complementary and alternative medicine (update 2015)

https://policybase.cma.ca/en/permalink/policy11529
Date
2015-May-30
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Counterfeit Drugs

https://policybase.cma.ca/en/permalink/policy9068
Date
2007-Dec-01
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Health systems, system funding and performance
Resolution
The Canadian Medical Association calls on the Government of Canada to: - implement an anti-counterfeit drugs strategy which could include track-and-trace technology, severe penalties for infractions, and an alert network to encourage reporting by health professionals and patients; and - work with other countries and international organizations on a global effort to stop drug counterfeiting.
Policy Type
Policy resolution
Last Reviewed
2015-Feb-28
Date
2007-Dec-01
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Health systems, system funding and performance
Resolution
The Canadian Medical Association calls on the Government of Canada to: - implement an anti-counterfeit drugs strategy which could include track-and-trace technology, severe penalties for infractions, and an alert network to encourage reporting by health professionals and patients; and - work with other countries and international organizations on a global effort to stop drug counterfeiting.
Less detail

Delegated professional prescribing

https://policybase.cma.ca/en/permalink/policy8865
Date
2007-Aug-22
Topics
Health systems, system funding and performance
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association affirms that within a multidisciplinary practice delegated professional prescribing is only acceptable when led by a physician clinical leader with ultimate responsibility for patient care.
Policy Type
Policy resolution
Last Reviewed
2014-Mar-01
Date
2007-Aug-22
Topics
Health systems, system funding and performance
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association affirms that within a multidisciplinary practice delegated professional prescribing is only acceptable when led by a physician clinical leader with ultimate responsibility for patient care.
Less detail

Direct-to-consumer advertising

https://policybase.cma.ca/en/permalink/policy8905
Date
2007-Aug-22
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the federal government to strengthen laws that ban direct-to-consumer advertising of prescription drugs to prohibit the "disguised" advertisements that promote drugs without naming them.
Policy Type
Policy resolution
Last Reviewed
2014-Mar-01
Date
2007-Aug-22
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association urges the federal government to strengthen laws that ban direct-to-consumer advertising of prescription drugs to prohibit the "disguised" advertisements that promote drugs without naming them.
Less detail

Drug product substitution

https://policybase.cma.ca/en/permalink/policy806
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Policy Type
Policy resolution
Last Reviewed
2017-Mar-04
Date
1987-Aug-25
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.
Less detail

26 records – page 1 of 3.